Literature DB >> 19487160

Natural killer and gammadelta T cells in haematological malignancies: enhancing the immune effectors.

Jérôme Rey1, Caroline Veuillen, Norbert Vey, Réda Bouabdallah, Daniel Olive.   

Abstract

Human natural killer (NK) and gamma delta (gammadelta) T cells are potent effectors involved in the destruction of abnormal cells. Accumulating clinical and experimental data point towards a key role for NK cells and gammadelta T cells in the control of most, if not all, haematological malignancies. This review focuses on the alterations in these effector cells found in patients with haematological malignancies, which might explain an escape from innate immune surveillance. We discuss new anti-cancer drugs that target these effector cells indirectly or directly. Finally, we review future strategies that offer the possibility of enhancing the effector functions of NK and gammadelta T cells against haematological malignancies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19487160     DOI: 10.1016/j.molmed.2009.04.005

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  18 in total

Review 1.  Biological therapy and the immune system in patients with chronic myeloid leukemia.

Authors:  Peter Rohon
Journal:  Int J Hematol       Date:  2012-06-04       Impact factor: 2.490

2.  Effect of Yiqi Bushen Granule (益气补肾颗粒) on the peripheral natural killer cell and γ δ T-cell in the patients with minimal residual leukemia.

Authors:  Yong-gang Xu; Rou Ma; Xiao-hong Yang; Xu-dong Tang; Shu-zhen Sun
Journal:  Chin J Integr Med       Date:  2010-09-25       Impact factor: 1.978

Review 3.  Vγ9Vδ2 T cell-based immunotherapy in hematological malignancies: from bench to bedside.

Authors:  Barbara Castella; Candida Vitale; Marta Coscia; Massimo Massaia
Journal:  Cell Mol Life Sci       Date:  2011-05-17       Impact factor: 9.261

Review 4.  Defining the nature of human γδ T cells: a biographical sketch of the highly empathetic.

Authors:  Shirin Kalyan; Dieter Kabelitz
Journal:  Cell Mol Immunol       Date:  2012-10-22       Impact factor: 11.530

5.  Targeting γδ T cells for immunotherapy of HIV disease.

Authors:  C David Pauza; David J Riedel; Bruce L Gilliam; Robert R Redfield
Journal:  Future Virol       Date:  2011-01-01       Impact factor: 1.831

6.  Solute carrier 11A1 is expressed by innate lymphocytes and augments their activation.

Authors:  Jodi F Hedges; Emily Kimmel; Deann T Snyder; Maria Jerome; Mark A Jutila
Journal:  J Immunol       Date:  2013-03-18       Impact factor: 5.422

Review 7.  Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy.

Authors:  Yuan Hu; Zhi-Gang Tian; Cai Zhang
Journal:  Acta Pharmacol Sin       Date:  2017-09-07       Impact factor: 6.150

Review 8.  Hematological malignancies escape from NK cell innate immune surveillance: mechanisms and therapeutic implications.

Authors:  Laure Farnault; Carole Sanchez; Céline Baier; Thérèse Le Treut; Régis T Costello
Journal:  Clin Dev Immunol       Date:  2012-08-01

9.  Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile.

Authors:  Anna Kreutzman; Peter Rohon; Edgar Faber; Karel Indrak; Vesa Juvonen; Veli Kairisto; Jaroslava Voglová; Marjatta Sinisalo; Emília Flochová; Jukka Vakkila; Petteri Arstila; Kimmo Porkka; Satu Mustjoki
Journal:  PLoS One       Date:  2011-08-09       Impact factor: 3.240

Review 10.  Empowering gamma delta T cells with antitumor immunity by dendritic cell-based immunotherapy.

Authors:  Heleen H Van Acker; Sébastien Anguille; Viggo F Van Tendeloo; Eva Lion
Journal:  Oncoimmunology       Date:  2015-04-01       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.